From: Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
Locoregional Tx
# pts
# pts achieving ≥1yr
disease control
CNS, surgery and/or RT
9/80 (11%)
5/9 (56%)
Non-CNS, surgery
11/80 (14%)
8/11 (73%)
Non-CNS, RT
6/80 (8%)
3/6 (50%)
Ablation
2/80 (3%)
1/2 (50%)